Stockreport

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics, Inc.  (APRE) 
PDF DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology c [Read more]